LU91852I2 - Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium - Google Patents

Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium

Info

Publication number
LU91852I2
LU91852I2 LU91852C LU91852C LU91852I2 LU 91852 I2 LU91852 I2 LU 91852I2 LU 91852 C LU91852 C LU 91852C LU 91852 C LU91852 C LU 91852C LU 91852 I2 LU91852 I2 LU 91852I2
Authority
LU
Luxembourg
Prior art keywords
tegafur
pharmaceutically acceptable
acceptable salt
gimeracil
oteracil
Prior art date
Application number
LU91852C
Other languages
English (en)
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of LU91852I2 publication Critical patent/LU91852I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
LU91852C 1991-05-27 2011-08-03 Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium LU91852I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP12124791 1991-05-27
PCT/JP1992/000656 WO1992021345A1 (fr) 1991-05-27 1992-05-22 Composition, methode et trousse pour le traitement des tumeurs par stimulation de l'activite antitumorale

Publications (1)

Publication Number Publication Date
LU91852I2 true LU91852I2 (fr) 2011-10-03

Family

ID=14806544

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91852C LU91852I2 (fr) 1991-05-27 2011-08-03 Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium

Country Status (14)

Country Link
US (1) US5525603A (fr)
EP (1) EP0543015B1 (fr)
JP (1) JP2614164B2 (fr)
KR (1) KR0148589B1 (fr)
AT (1) ATE173165T1 (fr)
AU (1) AU654555B2 (fr)
CA (1) CA2087540C (fr)
DE (2) DE122011100040I2 (fr)
DK (1) DK0543015T3 (fr)
ES (1) ES2124257T4 (fr)
HU (1) HU211987A9 (fr)
LU (1) LU91852I2 (fr)
TW (1) TW209833B (fr)
WO (1) WO1992021345A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
NZ330360A (en) * 1997-06-02 1999-03-29 Hoffmann La Roche 5'-deoxy-cytidine derivatives, their manufacture and use as antitumoral agents
JPH11116564A (ja) * 1997-10-09 1999-04-27 Otsuka Chem Co Ltd クロモン誘導体
US6005098A (en) * 1998-02-06 1999-12-21 Hoffmann-La Roche Inc. 5'deoxycytidine derivatives
WO2000021956A1 (fr) * 1998-10-12 2000-04-20 Leonidov Nikolai B Nouvelle modification cristalline de 5-fluoro-1-(tetrahydro-2-furyl)-uracyle, et composes complexes a base de cette modification ayant une activite antitumorale
JP2002255828A (ja) * 2001-02-28 2002-09-11 Ajinomoto Co Inc 抗腫瘍剤
AU2003235761A1 (en) * 2002-01-14 2003-07-24 Novartis Ag Combinations comprising epothilones and anti-metabolites
DK1604991T3 (da) * 2003-03-14 2009-01-05 Taiho Pharmaceutical Co Ltd Antitumorvirkningsforstærker og antitumormiddel
JP5376758B2 (ja) * 2004-04-29 2013-12-25 大鵬薬品工業株式会社 テガフールの投与に起因する消化器毒性を軽減する方法
KR100844477B1 (ko) 2004-06-09 2008-07-07 다이호야쿠힌고교 가부시키가이샤 항종양 효과 증강제, 항종양제 및 암 치료 방법
CN101912399B (zh) * 2005-04-01 2012-05-23 大鹏药品工业株式会社 放射线治疗增强剂
JP4994618B2 (ja) * 2005-08-11 2012-08-08 学校法人北里研究所 Ｔｓ−１／カンプトテシン類による化学放射線療法
US8198264B2 (en) * 2006-04-28 2012-06-12 National Cancer Center Method for treating head and neck cancer
CN101921227B (zh) * 2007-04-03 2012-09-05 南京工业大学 5-氯-4-羟基-2(1h)-吡啶酮晶型及其制备方法和应用
TWI468188B (zh) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
WO2009139085A1 (fr) 2008-05-12 2009-11-19 静岡県 Agent antitumoral, kit et procédé de traitement du cancer
WO2010104035A1 (fr) 2009-03-12 2010-09-16 学校法人近畿大学 Procédé permettant de prédire l'efficacité thérapeutique de la chimiothérapie sur le cancer du poumon non à petites cellules
HUE029171T2 (hu) 2009-03-31 2017-02-28 Delta-Fly Pharma Inc RNSI molekula timidilát-szintázhoz és alkalmazása
TW201043237A (en) 2009-04-22 2010-12-16 Taiho Pharmaceutical Co Ltd Method for predicting a therapeutic effect of the chemotherapy for renal cell cancer
CA2761243A1 (fr) 2009-05-12 2010-11-18 Taiho Pharmaceutical Co., Ltd. Agent anti-tumoral comprenant une association medicamenteuse de tegafur-gimeracil-oteracil potassium et de l'oxaliplatine
ES2619937T3 (es) 2009-10-27 2017-06-27 Delta-Fly Pharma, Inc. Nuevo derivado de 5-fluorouracilo
CN102309491B (zh) * 2010-07-02 2015-06-10 天津金耀集团有限公司 一种替加氟、吉美斯特复方注射液
JPWO2012105486A1 (ja) 2011-01-31 2014-07-03 大鵬薬品工業株式会社 １日１回隔日投与を特徴とするテガフール含有組成物
JPWO2012157647A1 (ja) 2011-05-16 2014-07-31 大鵬薬品工業株式会社 胃癌患者に対するテガフール・ギメラシル・オテラシルカリウム配合剤及びｅｇｆｒ阻害剤からなる化学療法の選択方法
MY167883A (en) 2011-05-25 2018-09-26 Taiho Pharmaceutical Co Ltd Dry-coated tablet containing tegafur, gimeracil and oteracil potassium
CN103159673B (zh) * 2011-12-12 2015-02-04 山东新时代药业有限公司 一种制备吉美嘧啶的精制方法
AU2013233094A1 (en) 2012-03-16 2014-10-23 Taiho Pharmaceutical Co., Ltd. Novel antitumor agent comprising combination of three agents
TW201400810A (zh) * 2012-06-01 2014-01-01 Taiho Pharmaceutical Co Ltd 對胃癌患者選擇化學療法之方法
CN114436822B (zh) * 2022-01-12 2024-04-16 厦门稀土材料研究所 一枝蒿酮酸和生物碱复盐及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111420A (en) * 1979-02-20 1980-08-28 Ono Pharmaceut Co Ltd Antitumorigenic agent
JPS562913A (en) * 1979-06-21 1981-01-13 Ono Pharmaceut Co Ltd Antitumor agent
JPS5646867A (en) * 1979-09-25 1981-04-28 Ono Pharmaceut Co Ltd Pyridone derivative, its preparation and antineoplasmic agent
DK175432B1 (da) * 1984-10-30 2004-10-18 Otsuka Pharma Co Ltd Middel til forögelse af anticancervirkningen af anticancerforbindelser
JPS62155215A (ja) * 1984-11-30 1987-07-10 Otsuka Pharmaceut Co Ltd 抗腫瘍活性増強剤
NL194430C (nl) * 1989-01-05 2002-04-04 Otsuka Pharma Co Ltd Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking.
JPH0578249A (ja) * 1991-09-20 1993-03-30 Taiho Yakuhin Kogyo Kk ５−フルオロウラシル類により起こる嘔気・嘔吐の防止及び治療剤

Also Published As

Publication number Publication date
DE69227571T2 (de) 1999-04-29
EP0543015A4 (en) 1994-06-01
EP0543015A1 (fr) 1993-05-26
EP0543015B1 (fr) 1998-11-11
DE122011100040I1 (de) 2011-11-24
AU1791292A (en) 1993-01-08
CA2087540A1 (fr) 1992-11-28
DK0543015T3 (da) 1999-07-26
ES2124257T3 (es) 1999-02-01
HU211987A9 (en) 1996-01-29
US5525603A (en) 1996-06-11
JP2614164B2 (ja) 1997-05-28
DE122011100040I2 (de) 2012-08-09
WO1992021345A1 (fr) 1992-12-10
TW209833B (fr) 1993-07-21
ES2124257T4 (es) 2012-03-23
CA2087540C (fr) 1999-01-19
KR0148589B1 (ko) 1998-11-02
ATE173165T1 (de) 1998-11-15
DE69227571D1 (de) 1998-12-17
AU654555B2 (en) 1994-11-10

Similar Documents

Publication Publication Date Title
LU91852I2 (fr) Tegafur, gimeracil et oteracil ou un de ses sels pharmaceutiquement acceptables, en particulier le sel potassium
NO2006018I1 (no) Entekavir:(2-amino-1,9-dihydro-9Ä(1S,3R,4S)-4hydroksy-3-(hydroksymetyl)-2-metylencyklopentylÜ-6H-purin-6-on og hydrater derav, saerlig monohydrat
CA2209598A1 (fr) Composes d'arylpurine et d'heteroarylpurine
HK1086256A1 (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
FR2677884B1 (fr) Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
PL293316A1 (en) Method of obtaining quinozolinone derivatives
FI900085A (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(pyrimidin- ja kondensoitu pyrimidin-4-oni)etyyli-piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
ATE229516T1 (de) Benzofuran-4-carboxamide
EP0322738A3 (fr) Dérivés de la benzylidène pour l'inhibition des processus de prolifération dans les cellules des mammifères
AU2097492A (en) Composition and method for treating cancer
DE69414019D1 (de) Bicyclische Stichstoff enthaltende Derivate als Prolyl-Endopeptidase Inhibitoren
ATE191317T1 (de) Verwendung von beta-aminopropionsäure-derivaten als fungizide
AU2101592A (en) Piperidine derivatives
EP0202062A3 (fr) Dérivés de quinuclidine
ES2087247T3 (es) Inhibidor de aldosa reductasa.
ATE374189T1 (de) Phthalazinon-derivate als pde 4 hemmer
CA2058398A1 (fr) Derives d'acide 1,4-benzothiazine-2-acetique; methode de preparation
ATE233739T1 (de) Neue parabansäure-derivate als aldose-reduktase inhibitoren
JPS574977A (en) 2-guanidinothiazole derivative
EP1028118A4 (fr) Procede de production de composes de 3 cephems
EP0245004A3 (fr) Composés antihypercholestérolémiques
ES8601969A1 (es) Un procedimiento para preparar derivados de piridona
WO2003099819A3 (fr) Derives d'oxophenyl-cyclohexyl-propanolamine, leur preparation et leur application en therapeutique
MX9704257A (es) Proceso para la preparacion de compuestos de 5-(alcoximetil) -2,3-piridinodicarboximida.
DE69025817D1 (de) 3-Keto-HMG-CoA Reduktase-Inhibitoren